Evidence map›Paper›PMID 37016326›Full record

Trial reportBMC pregnancy and childbirth2023

A pilot study to compare propranolol and misoprostol versus misoprostol and placebo for induction of labor in primigravidae; a randomized, single-blinded, placebo-controlled trial.

Ahmed Sherif Abdel Hamid, Hazem El Zeneiny, Ahmed Fathy, Maii Nawara

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC pregnancy and childbirth, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04533841 (Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor In Primigravidas), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04533841 phase2completednot on this map

Propranolol and Misoprostol Versus Misoprostol Alone for Induction of Labor In Primigravidas

TypeinterventionalSponsorAhmed mohamed fathy ismailRan2020 to 2020Enrolled128ConditionsInduction of Labor Affected Fetus / NewbornArmsMisoprostol, Placebo, Propranolol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ahmed Sherif Abdel HamidDepartment of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Abbaseyya Square, Cairo, Egypt. ahmedsherif@med.asu.edu.eg.ORCID http://orcid.org/0000-0002-8495-5909
Hazem El ZeneinyDepartment of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Abbaseyya Square, Cairo, Egypt.
Ahmed FathyDepartment of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Abbaseyya Square, Cairo, Egypt.
Maii NawaraDepartment of Obstetrics & Gynecology, Faculty of Medicine, Ain Shams University, Abbaseyya Square, Cairo, Egypt.
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Induction of labor is the most common obstetric procedure in daily practice. Introducing propranolol as a new drug to augment the action of prostaglandins will help in the induction process and decrease CS rates. Several researchers have used propranolol in the augmentation of labor.

aimThis pilot study compares propranolol and misoprostol versus misoprostol alone for labor induction in primigravids.

methodsThis is a Randomized clinical trial, single-blinded, placebo-controlled trial at Ain Shams University Maternity hospital. This study included 128 pregnant full-term primigravid women candidates for labor induction, randomized into two groups. All candidates underwent labor induction with 25 µg of vaginal misoprostol. Group I received 20 mg of oral propranolol tablets, while group II received sugary pills as a placebo. Candidates who responded successfully to induction were assessed for possible augmentation of labor by amniotomy or oxytocin infusion. The Primary outcome was induction to delivery interval, while the secondary outcomes were the duration of the latent phase, mode of delivery, and APGAR score of the neonate.

resultsThe induction-delivery time was (11.8 ± 8.1 h. vs. 12.6 ± 8.9 h., P value = 0.027) and the duration of the latent phase of labor (7.9 ± 5.6 h. vs. 9.2 ± 6.03 h., P value = 0.017) were significantly shorter in the group of misoprostol and propranolol compared to the group of misoprostol and placebo. There was no statistically significant difference between both groups' mode of delivery, indications for cesarean section, misoprostol, and oxytocin doses, or neonatal outcome. (P value > 0.05).

conclusionPropranolol, when used with misoprostol for induction of labor, results in augmentation of action of misoprostol and a significantly shorter induction-delivery interval.

trial registrationWe retrospectively registered this trial in clinicaltrial.gov on 01/09/2020 (NCT04533841). https://clinicaltrials.gov/ct2/show/NCT04533841.

Indexed as

MisoprostolOxytocicsPropranololAdministration, IntravaginalCesarean SectionFemaleHumansInfant, NewbornLabor, InducedOxytocinPilot ProjectsPregnancyMisoprostolOxytocicsOxytocinPropranololInduction of laborMisoprostolPropranolol

Identifiers

PMID37016326
PMCPMC10071722
OpenAlexW4362555227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.